Trial Profile
A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects with Wnt-5a Low Colon Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Foxy 5 (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NeoFox
- Sponsors WntResearch
- 08 Dec 2022 Planned End Date changed from 30 Nov 2022 to 14 Dec 2024.
- 08 Dec 2022 Planned primary completion date changed from 14 Mar 2022 to 14 Dec 2024.
- 08 Dec 2022 Status changed from recruiting to active, no longer recruiting.